Clearmind Medicine Publishes International Patent for Novel MDMA Treatment

Clearmind Medicine Inc., based in Vancouver, Canada, has recently announced the filing of an international patent application under the Patent Cooperation Treaty (PCT) for a groundbreaking therapeutic combination of 3,4-Methylenedioxymethamphetamine (MDMA) with N-Acylethanolamines. This development is part of their ongoing collaboration with SciSparc Ltd., a clinical-stage pharmaceutical company focused on treating central nervous system disorders.

Clearmind Medicine, a clinical-stage biotech company, is dedicated to discovering and developing novel psychedelic-derived therapeutics to address major health issues that are currently under-treated. The new patent application underlines their strategic collaboration with SciSparc Ltd., which aims to create innovative combination therapies integrating psychedelic molecules with the N-Acylethanolamines family, such as Palmitoylethanolamide (PEA).

To date, the partnership has led to the filing of thirteen patents with the U.S. Patent and Trademark Office, as well as in various international jurisdictions. Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, highlighted the significance of this development by pointing out that while MDMA has shown substantial clinical benefits as a standalone treatment, it also carries potential dose-limiting toxicities. The combination of MDMA with PEA is designed to mitigate these safety concerns, as raised by the FDA, by reducing the required dosage of MDMA, thereby lowering potential risks while maintaining therapeutic efficacy.

Clearmind Medicine's unique approach to combining psychedelic molecules with N-Acylethanolamines aims to open new avenues in treating mental health disorders and addictions. This innovative strategy reflects their commitment to bringing effective and safer treatments to the market.

Clearmind Medicine Inc. focuses on the discovery and development of novel psychedelic-derived therapeutics to address widespread and underserved health issues like alcohol use disorder. Their primary goal is to research and develop psychedelic-based compounds and aim to commercialize them as regulated medicines, foods, or supplements. The company’s intellectual property portfolio includes nineteen patent families with 29 granted patents, and they continue to seek additional patents for their compounds and remain opportunistic regarding the acquisition of new intellectual property.

Clearmind’s shares are traded on Nasdaq under the symbol "CMND" and on the Frankfurt Stock Exchange under the symbol “CWY0”.

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, is led by a team of experienced executives and scientists. The company focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. SciSparc is currently engaged in several drug development programs based on THC and non-psychoactive cannabidiol. Their key programs include SCI-110 for treating Tourette Syndrome and Alzheimer’s disease-related agitation, and SCI-210 for treating autism and status epilepticus. Additionally, SciSparc holds a controlling interest in a subsidiary that focuses on selling hemp seed oil-based products on the Amazon.com Marketplace.

This collaboration between Clearmind Medicine and SciSparc Ltd. represents a significant step forward in developing safer and more effective treatments for mental health and addiction disorders. By combining the therapeutic benefits of MDMA with the safety profile of N-Acylethanolamines, the partnership aims to overcome the challenges associated with MDMA's dose-limiting toxicities, thus paving the way for new treatment paradigms.